Neuroleptic Malignant Syndrome in the Trauma Intensive Care Unit: Diagnosis and Management of a Rare Disease in a Challenging Population
Overview
Affiliations
Neuroleptic malignant syndrome (NMS) is a life-threatening neurological disorder associated with the use of antipsychotic medications. Many of its classic signs, such as fever and altered mental status, are nonspecific in trauma intensive care unit (ICU) patients, and its rarity makes it a difficult diagnosis in this population. However, delays in treatment can be costly both in terms of hospital resources and patient outcomes. We herein report a case of a 54-year-old trauma patient with NMS precipitated by a combination of cocaine withdrawal and neuroleptic medications. Few cases of NMS in the intubated polytrauma patient have been described in the literature previously. Given the poor outcomes associated with this disorder, ICU patients would benefit from risk stratification and avoidance of neuroleptic medications in those at highest risk for NMS, particularly patients who are withdrawing from dopaminergic agents.
Yu B, Lee J, Kim Y, Park H, Jung J, Jo Y J Trauma Inj. 2024; 36(3):249-252.
PMID: 39381710 PMC: 11309282. DOI: 10.20408/jti.2022.0048.
Miller M, Zezetko A, Satodiya R Cureus. 2023; 15(2):e35538.
PMID: 37007397 PMC: 10058510. DOI: 10.7759/cureus.35538.
Ngo V, Guerrero A, Lanum D, Burgett-Moreno M, Fenati G, Barr S Clin Pract Cases Emerg Med. 2019; 3(1):16-23.
PMID: 30775657 PMC: 6366389. DOI: 10.5811/cpcem.2018.11.39667.